Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G sues Amway exec committee member for statements linking firm with satanism.

This article was originally published in The Tan Sheet

Executive Summary

PROCTER & GAMBLE SLANDER SUIT TARGETS AMWAY EXECUTIVE COMMITTEE MEMBER for "spreading false and malicious statements connecting P&G with satanism," P&G announced. The lawsuit, filed on Aug. 28 in U.S. District Court of Utah, alleges that "high ranking `diamond level'" Amway distributor Randy Haugen and other distributors "circulated and published" statements through Amway's Amvox communication system that "falsely and maliciously assert that the president of P&G appeared on a nationally televised talk show and discussed P&G's relationship to satanism and P&G's support for the church of satan." Haugen recently co-chaired the business operations of the Amway Distributors Association Council and currently sits on its executive committee.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS084263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel